Oncology Publications
The publications listed below are offered for informational purposes only and do not represent all publications to which X4 Pharmaceuticals or its collaboration partners have contributed or may contribute or that relate to X4 Pharmaceuticals’ product candidates. These publications are made available by third parties, and the content of any linked third-party site is the responsibility of the third party, not X4 Pharmaceuticals, and X4 Pharmaceuticals disclaims liability for the linked content.
Waldenstrom’s
Expert Rev Hematol. 2019 Jul 30:1-9. doi: 10.1080/17474086.2019.1649132. [Epub ahead of print]
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ1, Moreno DF2, Arbelaez MI3, Hunter ZR1, Treon SP1.
Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16088. [Epub ahead of print]
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Castillo JJ1,2, Xu L1, Gustine JN1,3, Keezer A1, Meid K1, Dubeau TE1, Liu X1, Demos MG1, Kofides A1, Tsakmaklis N1, Chen JG1, Munshi M1, Guerrera ML1, Chan GG1, Patterson CJ1, Yang G1,2, Hunter ZR1, Treon SP1,2.
Br J Haematol. 2015 Mar;168(5):701-7. doi: 10.1111/bjh.13200. Epub 2014 Nov 5.
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y1, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP.
Leukemia. 2015 Jan;29(1):169-76. doi: 10.1038/leu.2014.187. Epub 2014 Jun 10.
The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia.
Blood. 2014 Jun 26;123(26):4120-31. doi: 10.1182/blood-2014-03-564583. Epub 2014 Apr 7.
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
Roccaro AM1, Sacco A1, Jimenez C2, Maiso P1, Moschetta M1, Mishima Y1, Aljawai Y1, Sahin I1, Kuhne M3, Cardarelli P3, Cohen L4, San Miguel JF5, Garcia-Sanz R2, Ghobrial IM1.
Author information
CXCR4 General: Tumor Microenvironment
Clin Cancer Res. 2015 Oct 1;21(19):4278-85. doi: 10.1158/1078-0432.CCR-14-0914. Epub 2015 Jul 21.
Molecular Pathways: Targeting the CXCR4-CXCL12 Axis–Untapped Potential in the Tumor Microenvironment.
Renal
Oncotarget. 2017 Aug 19;8(44):77110-77120. doi: 10.18632/oncotarget.20363. eCollection 2017 Sep 29.
Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.
Santagata S1, Napolitano M1, D’Alterio C1, Desicato S2, Maro SD3, Marinelli L3, Fragale A4, Buoncervello M4, Persico F5, Gabriele L4, Novellino E3, Longo N5, Pignata S2, Perdonà S2, Scala S1.
Curr Cancer Drug Targets. 2012 Jul;12(6):693-702.
High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.
D’ Alterio C1, Portella L, Ottaiano A, Rizzo M, Carteni G, Pignata S, Facchini G, Perdona S, Di Lorenzo G, Autorino R, Franco R, La Mura A, Nappi O, Castello G, Scala S.
Author information
Department of Oncological Immunology, Istituto per lo Studio e la Cura dei Tumori “Pascale”, Naples, Italy.
Nat Med. 2013 Jan;19(1):50-6. doi: 10.1038/nm.3029. Epub 2012 Dec 9.
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
Vanharanta S1, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J.
Author information
Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Nature. 2003 Sep 18;425(6955):307-11.